Remitting neuropsychiatric symptoms in COVID-19 patients: Viral cause or drug effect?
David A Forero-PeñaMatthew M HernandezIriana Paola Mozo HerreraIván Bolívar Collado EspinalJoselyn Páez PazCarlos FerroDavid M Flora-NodaAndrea L MaricutoViledy L VelásquezNatasha A Camejo-AvilaEmilia Mia SordilloLourdes A Delgado NogueraLuis A Perez-GarciaCarlos G Morantes RodríguezMaría Eugenia LandaetaAlberto Paniz MondolfiPublished in: Journal of medical virology (2021)
Numerous reports of neuropsychiatric symptoms highlighted the pathologic potential of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its relationship the onset and/or exacerbation of mental disease. However, coronavirus disease 2019 (COVID-19) treatments, themselves, must be considered as potential catalysts for new-onset neuropsychiatric symptoms in COVID-19 patients. To date, immediate and long-term neuropsychiatric complications following SARS-CoV-2 infection are currently unknown. Here we report on five patients with SARS-CoV-2 infection with possible associated neuropsychiatric involvement, following them clinically until resolution of their symptoms. We will also discuss the contributory roles of chloroquine and dexamethasone in these neuropsychiatric presentations.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- coronavirus disease
- multiple sclerosis
- sleep quality
- chronic obstructive pulmonary disease
- emergency department
- squamous cell carcinoma
- highly efficient
- mechanical ventilation
- radiation therapy
- risk factors
- locally advanced
- single molecule
- disease activity
- rectal cancer
- electronic health record
- physical activity
- extracorporeal membrane oxygenation